Business
Repligen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance
Fourth quarter revenue of $198 million, a year-over-year increase of 18% as reported, 14% organic with continued momentum in orders in the quarterFull year 2025 revenue of $738 million, a year-over-year increase of 16% for both reported and organic non-COVIDFull year 2026 revenue guidance of $810 million - $840 million, 10% to 14% reported revenue growth, 9% to 13% organic and adjusted operating margin expansion of 150 bps at the midpoint WALTHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Replige
About this update from Repligen Corporation
[{"type":"image","alt":"Repligen Corporation","displaySize":"","headline":null,"caption":"Repligen Corporation","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":85,"url":"https://media.zenfs.com/en/globenewswire.com/1faf8a83b456dc1170425e717ec9aa66"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/N.gKI5y8ci7i4y7StetPJQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExOTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/1faf8a83b456dc1170425e717ec9aa66","width":300,"height":85}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Fourth quarter revenue of $198 million, a year-over-year increase of 18% as reported, 14% organic with continued momentum in orders in the quarter","length":146,"tagName":"p"}]},{"val":[{"type":"text","content":"Full year 2025 revenue of $738 million, a year-over-year increase of 16% for both reported and organic non-COVID","length":112,"tagName":"p"}]},{"val":[{"type":"text","content":"Full year 2026 revenue guidance of $810 million - $840 million, 10% to 14% reported revenue growth, 9% to 13% organic and adjusted operating margin expansion of 150 bps at the midpoint","length":184,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":442,"olType":false},{"type":"text","content":"WALTHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its fourth quarter of 2025, covering the three- and twelve- month periods ended December 31, 2025. The Company is also providing financial guidance for the full year 2026.","length":366,"tagName":"p"},{"type":"text","content":"Olivier Loeillot, President and Chief Executive Officer of Repligen said, “We had a great finish to 2025 with 14% organic growth in the quarter led by Analytics and Proteins. As a result, we exceeded the high end of our October revenue and adjusted operating income guidance. We are thrilled by our strong performance in 2025 with 16% organic non-COVID growth driven by traction across our differentiated portfolio, while continuing to expand margins.","length":456,"tagName":"p"},{"type":"text","content":"“As we turn the page to 2026, we are excited about our product portfolio, the team we've built, and the strategy we are executing. We are investing with intention: expanding...